Figure 5: Ex-vivo kidney perfusion platform. RMSCs delivered into glomeruli, eventually migrating into mesangial areas where injury is detected. A- X250- Glomerulus showing MSCs in mesangial areas. B- MSCs in mesangium (no curcumin); C- MSCs in mesangium after curcumin treatment (observation for 48 hours post-treatment with glomerulopathic LCs and then injection of MSCs). AX350; B and CX750- Overall view of glomerulus with MSCs. The number of RMSCs into sites of injury is markedly increased when curcumin is administered before RMSCs are injected through the renal artery (compare B with C).